SODIUM IODIDE I-123

First approved in 1976

Details

Stereochemistry	ACHIRAL
Molecular Formula	I.Na
Molecular Weight	145.89536722
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[123I-]

InChI

InChIKey=FVAUCKIRQBBSSJ-VVUPZWBASA-M

InChI=1S/HI.Na/h1H;/q;+1/p-1/i1-4;

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	HI
Molecular Weight	123.91354
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/018671s016lbl.pdf / https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16d8fe7-4480-40d1-8951-ad65f7f15438 | https://www.drugs.com/pro/sodium-iodide-i-123.html

Iodide ion I-123 is the most suitable isotope of iodine for the diagnostic study of thyroid diseases. Sodium Iodide I 131 Capsules Diagnostic is indicated for use in adults for: Assessment of thyroid function using radioactive iodine (RAI) uptake test and Imaging the thyroid (scintigraphy). The following adverse reaction has been described elsewhere in the labeling: Hypersensitivity Reactions. The following adverse reactions have been identified during post-approval use from Sodium Iodide I 131 Capsules Diagnostic: Gastrointestinal disorders (vomiting, nausea, and diarrhea); General disorders and administration site conditions (local thyroid swelling); Immune system disorders (hypersensitivity reactions); Skin and subcutaneous tissue disorders (itching, rash, hives, and erythema). Certain drugs and iodine-containing foods interfere with the accumulation of radioiodide by the thyroid.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Thyroid diseases 2 Sources: http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017630	Diagnostic		Approved 8583	SODIUM IODIDE I 123 Approved Use Unknown Launch Date 1976

Sample Use Guides

In Vivo Use Guide

The recommended oral dose range for diagnostic studies of thyroid function in the average adult patient (70 kg) is 3.7-14.8 MBq (100-400 uCi) of Sodium Iodide I-123. The lower portion of the range 3.7 MBq (100 uCi) is recommended for uptake studies alone, and the higher portion 14.8 MBq (400 uCi) for thyroid imaging.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:07:54 GMT 2025` Edited by `admin` on `Mon Mar 31 18:07:54 GMT 2025`
Record UNII	29UKX3A616
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SODIUM IODIDE I-123

Common Name

English

SODIUM IODIDE I 123

Preferred Name

English

SODIUM IODIDE, I-123

Common Name

English

SODIUM IODIDE (123I)

Common Name

English

SODIUM IODIDE I-123 [ORANGE BOOK]

Common Name

English

SODIUM IODIDE (123 I)

Common Name

English

SODIUM IODIDE I123

Common Name

English

SODIUM IODIDE I 123 [USP IMPURITY]

Common Name

English

SODIUM IODIDE-123

Common Name

English

SODIUM IODIDE,I-123 [VANDF]

Common Name

English

Sodium iodide (123 i) [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QV09FX02